Evoke Pharma Operating Margin 2012-2025 | EVOK
Current and historical operating margin for Evoke Pharma (EVOK) over the last 10 years. The current operating profit margin for Evoke Pharma as of March 31, 2025 is -43.80%.
| Evoke Pharma Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2025-03-31 |
$0.01B |
$0.00B |
-33.33% |
| 2024-12-31 |
$0.01B |
$-0.01B |
-45.45% |
| 2024-09-30 |
$0.01B |
$-0.01B |
-60.00% |
| 2024-06-30 |
$0.01B |
$-0.01B |
-77.78% |
| 2024-03-31 |
$0.01B |
$-0.01B |
-114.29% |
| 2023-12-31 |
$0.01B |
$-0.01B |
-133.33% |
| 2023-09-30 |
$0.01B |
$-0.01B |
-160.00% |
| 2023-06-30 |
$0.00B |
$-0.01B |
-200.00% |
| 2023-03-31 |
$0.00B |
$-0.01B |
-266.67% |
| 2022-12-31 |
$0.00B |
$-0.01B |
-400.00% |
| 2022-09-30 |
$0.00B |
$-0.01B |
-800.00% |
| 2022-06-30 |
$0.00B |
$-0.01B |
-800.00% |
| 2022-03-31 |
$0.00B |
$-0.01B |
-800.00% |
| 2021-12-31 |
$0.00B |
$-0.01B |
-900.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.004B |
$0.010B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
